Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Complete Response × Radiation × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 28 Glioblastoma 26 Breast Neoplasms 19 Lung Neoplasms 18 Carcinoma, Non-Small-Cell Lung 14 Oropharyngeal Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 10 Gliosarcoma 9 Brain Neoplasms 9 Uterine Cervical Neoplasms 8 Urinary Bladder Neoplasms 8 Sarcoma 7 Melanoma 7 Esophageal Neoplasms 7 Astrocytoma 7 Triple Negative Breast Neoplasms 6 Mouth Neoplasms 6 Head and Neck Neoplasms 6 Glioma 6 Rectal Neoplasms 5 Pancreatic Neoplasms 5 Neoplasm Metastasis 5 Carcinoma, Squamous Cell 5 Adenocarcinoma Of Esophagus 5 Neoplasms 4 Laryngeal Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Carcinoma, Hepatocellular 4 Carcinoma 4 Adenocarcinoma of Lung 4

Interventions

Carboplatin 4 pembrolizumab 3 Paclitaxel 3 Capecitabine 3 Azacitidine 3 venetoclax 2 pertuzumab 2 olaparib 2 durvalumab 2 Trastuzumab 2 Standard of Care 2 Oxaliplatin 2 Observation 2 Irinotecan 2 Immunotherapy 2 Immune Checkpoint Inhibitors 2 Chemoradiotherapy 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 taxane 1 talazoparib 1 tagraxofusp 1 sarilumab 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡